The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Molecular mechanisms of cisplatin resistance in cervical cancer
Open accessAbstract
Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%-20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 15×
“4 Epigenetic drugs such as 5-azacytidine have been shown to block aberrant DNA methylation and thus reverse CPR. 64 Combination of cisplatin and 5-aza-2 ′ -deoxycytidine, a demethylating agent, significantly enhances the sensitivity to cisplatin in ME180 parent cells and the CPR subclones, and the removal of 5-aza-2 ′…”
BackgroundInfluentialMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 7×
“In CPR cancer cells, inter- and intra-strand DNA adducts often fail to trigger apoptotic cascade for many reasons.(15) Tumor”
BackgroundInfluentialA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751
Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676
Requirement for ERK Activation in Cisplatin-induced Apoptosis
Wang, X., Martindale, J. L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004583200 · Cited by 675
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Mistry, P., Kelland, L., Abel, G., Sidhar, S., & Harrap, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.279 · Cited by 261
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249
Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F., & Barni, S. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.01.042 · Cited by 207
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance
Brozovic, A., & Osmak, M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.007 · Cited by 204
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K. R., Kassack, M. U., Osmak, M., & Jaehde, U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.003 · Cited by 174
Xu, Y., Yu, H., Qin, H., Kang, J., Yu, C., Zhong, J., Su, J., Li, H., & Sun, L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.034 · Cited by 166
Pariente, R., Pariente, J. A., Rodríguez, A. B., & Espino, J. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12288 · Cited by 151
Brozović, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M., & Kaina, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20522 · Cited by 148
Wang, F., Liu, M., Li, X., & Tang, H. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.01.016 · Cited by 141
A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431
Castagna, A., Antonioli, P., Astner, H., Hamdan, M., Righetti, S. C., Perego, P., Zunino, F., & Righetti, P. G. (2004) · PROTEOMICS · doi:10.1002/pmic.200400835 · Cited by 139
Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Ea, C.-K., & Cheng, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00908-5 · Cited by 136
High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer
Liu, S., & Zheng, P. (2013) · Oncotarget · doi:10.18632/oncotarget.1578 · Cited by 135
Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology
Yoo, B. K., Emdad, L., Lee, S., Su, Z.-Z., Santhekadur, P. K., Chen, D., Gredler, R., Fisher, P. B., & Sarkar, D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.008 · Cited by 134
Liedert, B., Materna, V., Schadendorf, D., Thomale, J., & Lage, H. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12313.x · Cited by 129
Li, L., Wei, X. H., Pan, Y., Li, H. C., Yang, H. K., He, Q., Pang, Y., Shan, Y., Xiong, F., Shao, G., et al. (2010) · Oncogene · doi:10.1038/onc.2010.303 · Cited by 120
Mellish, K. J., Kèlland, L. R., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 115
Autophagic pathways as new targets for cancer drug development
Liu, B., Cheng, Y., Liu, Q., Bao, J., & Yang, J. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.118 · Cited by 109
Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells
Roy, M., & Mukherjee, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.3.1403 · Cited by 103
Gallerne, C., Prola, A., & Lemaire, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.014 · Cited by 97
Şahin, K., Tuzcu, M., Başak, N., Çağlayan, B., Kılıç, Ü., Sahin, F., & Kucuk, O. (2012) · Journal of Oncology · doi:10.1155/2012/461562 · Cited by 96
Membrane Transporters as Mediators of Cisplatin Effects and Side Effects
Ciarimboli, G. (2012) · Scientifica · doi:10.6064/2012/473829 · Cited by 95
Chen, Y., Ke, G., Han, D., Liang, S., Yang, G. S., & Wu, X. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.10.014 · Cited by 87
Yokoyama, M. (2003) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.09.023 · Cited by 85
Biological and chemical inhibitors of NF‐κB sensitize SiHa cells to cisplatin‐induced apoptosis
Manickam, V., Anto, R. J., Nair, S. A., Varghese, M., & Karunagaran, D. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20116 · Cited by 82
Treatment of metastatic cervical cancer: Future directions involving targeted agents
Díaz-Padilla, I., Monk, B. J., MacKay, H. J., & Oaknin, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.006 · Cited by 82
Shen, D.-W., Akiyama, S.-I., Schoenlein, P. V., Pastan, I. H., & Gottesman, M. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.134 · Cited by 82
Ding, Z., Yang, X., Pater, A., & Tang, S. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2432 · Cited by 81
Sun, Y., Liu, J., Jin, L. G., Lin, S., Yang, Y., Sui, Y., & Shi, H. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.001 · Cited by 77
Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes
Shi, T.-Y., Cheng, X., Yu, K., Sun, M.-H., Shao, Z.-M., Wang, M., Zhu, M., He, J., Li, Q.-X., Chen, X.-J., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt001 · Cited by 76
Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ
Basu, A., & Tu, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.199 · Cited by 70
Enrichment and characterization of cancer stem-like cells from a cervical cancer cell line
Wang, L., Guo, H., Lin, C., Yang, L., & Wang, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2063 · Cited by 69
Zhu, K., Chen, L., Han, X., Wang, J., & Wang, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1633 · Cited by 69
Chao, C. C., Huang, Y. T., Ma, C. M., Chou, W.-I., & Lin‐Chao, S. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08844-3 · Cited by 69
Zhang, Y., & Shen, X. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2090 · Cited by 64
Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells
Wu, Z., Lu, H., & Chao, C. C. ‐. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.029 · Cited by 63
Enhancement of chemotherapeutic agent‐induced apoptosis by inhibition of NF‐κB using ursolic acid
Li, Y., Xing, D., Chen, Q., & Chen, W. R. (2010) · International Journal of Cancer · doi:10.1002/ijc.25044 · Cited by 62
Enhancement of Cisplatin Sensitivity in Human Cervical Cancer: Epigallocatechin-3-Gallate
Kılıç, Ü., Şahin, K., Tuzcu, M., Basak, N., Orhan, C., Elibol, B., Kılıç, E., Şahin, F., & Küçük, Ö. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2014.00028 · Cited by 62
Lanzi, C., Perego, P., Supino, R., Romanelli, S., Pensa, T., Carenini, N., Viano, I., Colangelo, D., Leone, R., Apostoli, P., et al. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00599-6 · Cited by 62
Chemosensitivity and p53–Bax pathway-mediated apoptosis in patients with uterine cervical cancer
Sultana, H., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., Sato, S., Kamazawa, S., Ohwada, M., Suzuki, M., & Terakawa, N. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg071 · Cited by 61
Cui, L., Wang, Y., Huang, Y., Yu, H., Huang, Y., Wu, L., & Huang, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052310 · Cited by 59
Liu, X., Wang, D., Liu, H., Feng, Y., Zhu, T., Zhang, L., Zhu, B., & Zhang, Y. (2014) · Cell Cycle · doi:10.4161/cc.28607 · Cited by 57
Casagrande, N., Paoli, M. D., Celegato, M., Borghese, C., Mongiat, M., Colombatti, A., & Aldinucci, D. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.08.041 · Cited by 56
Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells
Okada, T., Murata, K., Hirose, R., Matsuda, C., Komatsu, T., Ikekita, M., Nakawatari, M., Nakayama, F., Wakatsuki, M., Ohno, T., et al. (2013) · Scientific Reports · doi:10.1038/srep02899 · Cited by 53
Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel
Takara, K., Obata, Y., Yoshikawa, E., Kitada, N., Sakaeda, T., Ohnishi, N., & Yokoyama, T. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0226-5 · Cited by 53
He, F., Wang, Q., Zheng, X., Yan, J., Yang, L., Sun, H., Hu, L., Lin, Y., & Wang, X. (2012) · Oncology Reports · doi:10.3892/or.2012.1841 · Cited by 51
REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer Cells
Yang, L., Shi, T., Liu, F., Ren, C., Wang, Z., Li, Y.-Y., Tu, X., Yang, G. S., & Cheng, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120334 · Cited by 51
Seol, H., Ulak, R., Ki, K., & Lee, J. (2014) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.232.269 · Cited by 44
MDR1 Up-Regulated by Apoptotic Stimuli Suppresses Apoptotic Signaling
Sakaeda, T., Nakamura, T., Hirai, M., Kimura, T., Wada, A., Yagami, T., Kobayashi, H., Nagata, S., Okamura, N., Yoshikawa, T., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1020302825511 · Cited by 43
Quantitative Proteomic and Interaction Network Analysis of Cisplatin Resistance in HeLa Cells
Chavez, J. D., Hoopmann, M. R., Weisbrod, C. R., Takara, K., & Bruce, J. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019892 · Cited by 43
Jin, L., Shen, Q., Ding, S., Jiang, W., Jiang, L., & Zhu, X. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.04.005 · Cited by 39
Self-citationChen, J., Xiong, J., Liu, H., Chernenko, G. A., & Tang, S. (2002) · Oncogene · doi:10.1038/sj.onc.1205845 · Cited by 36
Nishikawa, K., Rosenblum, M. G., Newman, R. A., Pandita, T. K., Hittelman, W. N., & Donato, N. J. (1992) · PubMed · Cited by 32
Cisplatin treatment leads to changes in nuclear protein and microRNA expression
Zhang, G., Sun, L., Lu, X., Chen, Z., Duerksen-Hughes, P. J., Hu, H., Zhu, X., & Yang, J. (2012) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2012.03.004 · Cited by 31
Self-citationThe role of microRNA in the response to cisplatin treatment
Drayton, R. M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120055 · Cited by 31
The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer
Leisching, G. R., Loos, B., Botha, M. H., & Engelbrecht, A. (2015) · Toxicology · doi:10.1016/j.tox.2015.07.010 · Cited by 27
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells
Pouliot, L. M., Shen, D., Suzuki, T., Hall, M. D., & Gottesman, M. M. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.10.012 · Cited by 26
Improved Survival With Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H. Q., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitão, M. M., et al. (2014) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000451484.02983.78 · Cited by 26
Chao, C. C. ‐. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10564-6 · Cited by 23
Zhang, Y., Shu, Y., Wang, S. F., Da, B. H., Wang, Z. H., & Li, H. B. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-58 · Cited by 19
Bai, T., Tanaka, T., Yukawa, K., & Umesaki, N. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.497 · Cited by 16
Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.
Doherty, B., Lawlor, D., Gillet, J., Gottesman, M. M., O’Leary, J. J., & Stordal, B. (2014) · PubMed · Cited by 15
Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer
Meng, F., Tan, S., Liu, T., Song, H., & Lou, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-4319-9 · Cited by 14
Chao, C. C. ‐. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90059-0 · Cited by 14
Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G., Nictolis, M. D., Romaninï, C., & Biagini, G. (1995) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0301-2115(95)02216-t · Cited by 14
Synergistic Effect of Pyrrolidine Dithiocarbamate and Cisplatin in Human Cervical Carcinoma
Zheng, X., Lv, J., Shen, Q., Chen, Y., Zhou, Q., Zhang, W., & Zhu, X. (2014) · Reproductive Sciences · doi:10.1177/1933719114525272 · Cited by 14
Self-citationMartelli, L., Ragazzi, E., Mario, F. D., Basato, M., & Martelli, M. (2009) · PubMed · Cited by 13
Xu, Y., Wang, N., Ding, Y., Wang, C., Yu, Y., LIU, S., WANG, X., & Li, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2554 · Cited by 11
Ozfiliz-Kilbas, P., Arısan, E. D., Gürkan, A. Ç., Yerlikaya, P. O., Eralp, T. N., Doğanay, G. D., & Palavan-Ünsal, N. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.11.4475 · Cited by 9
Cited by
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 531
Cervical cancer therapies: Current challenges and future perspectives
Burmeister, C. A., Khan, S. F., Schäfer, G., Mbatani, N., Adams, T., Moodley, J., & Prince, S. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200238 · Cited by 474
Biological and clinical aspects of HPV-related cancers
Anna Szymonowicz, K., & Chen, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0370 · Cited by 402
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical and Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 366
Metadata
- Authors
- Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-06
- Volume
- 10
- Pages
- 1885
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2414600312
- Cited by
- 407
- References
- 86
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.